Harry P. Erba, M.D., Ph.D., is associate professor of internal medicine at the University of Michigan, Ann Arbor, Mich. In his role as one of the Group's three executive officers, he works with the lymphoma, leukemia and myeloma committees to develop clinical trials and offer advice to study coordinators as needed. In addition, Dr. Erba is a member of the Leukemia Committee and the Group's Board of Governors.

Dr. Erba received his bachelor's degree in biology from Yale University and his medical and doctoral degrees in biophysics from Stanford University. He completed his residency training in internal medicine and a fellowship in hematology and medical oncology at Brigham and Women's Hospital in Boston. In 1993, Dr. Erba was appointed instructor of medicine at Harvard Medical School, and has held assistant and associate physician appointments with the Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard University Health Services. He serves on the National Comprehensive Cancer Network Practice Guidelines Committees for acute myeloid leukemia, myelodysplastic syndrome, and chronic myeloid leukemia. He has been a faculty member at the University of Michigan since 1996 and his clinical and research interests include acute/chronic leukemia, myelodysplastic syndromes and other malignant blood diseases.

Carolyn J. Hoban, D.Sc., is an assistant professor of research in internal medicine at the University of Michigan, Ann Arbor, Mich. She joined the Southwest Oncology Group in November 2006 as an executive officer and oversees the development of the Group's protocols in translational medicine and cancer control. She also supervises activities that involve the Group's tumor and tissue banks. Dr. Hoban is a member of the Translational Medicine and Cancer Control Research committees, as well as the Board of Governors. Dr. Hoban works with the Translational Medicine Committee to bridge the flow of scientific knowledge between laboratory research and the Group's clinical trials. She also works to increase opportunities to develop targeted agents based on scientific knowledge learned from clinical investigation.

Dr. Hoban received her Bachelor of Science Degree from Tufts University, and her Master of Science Degree and Doctor of Science Degree from the Harvard University School of Public Health. She completed postdoctoral training at the MIT Center for Cancer Research. Dr. Hoban has more than 10 years' experience in the biotechnology and pharmaceutical industries in basic research and development, and in pharmacogenomics. Her personal research interests focus on understanding the microenvironment in which primary bone cancer develops, compared to how cancer cells from other areas of the body metastasize to the bone. Her personal goal is to better understand tumor biology so that targeted agents that intervene in the process of cancer growth can be developed to test in therapeutic trials.

Bruce G. Redman, D.O., is professor of internal medicine at the University of Michigan in Ann Arbor, Mich. As one of three executive officers in Southwest Oncology Group, Dr. Redman provides oversight for gastrointestinal, genitourinary, immunomolecular therapeutics and melanoma studies. He also is a member of the Group's Melanoma Committee and the Board of Governors.

Dr. Redman received his osteopathy degree in 1981 from the Chicago College of Osteopathic Medicine, where he also completed his training in internal medicine. He completed his fellowship in medical oncology at Wayne State University School of Medicine in 1987. From 1987 to 1997, he was a faculty member in the Division of Hematology and Oncology at Wayne State University, where he served as the program director of the Oncology Fellowship Training Program.

In 1997, Dr. Redman joined the faculty of the University of Michigan and has since been appointed co-director of the Tumor Immunology and Immunotherapy Program. His primary interest is in immunotherapeutic approaches to the treatment of cancer, especially as they apply to melanoma and kidney cancer. Dr. Redman is the author of more than 50 peer-reviewed publications and several book chapters.

Anne Schott, M.D., is assistant professor of internal medicine at the University of Michigan at Ann Arbor, Mich. One of three executive officers for Southwest Oncology Group, Dr. Schott monitors the protocol development activities of the breast cancer, early therapeutics, lung, head and neck, and special populations committees. She is a member of the Group's Board of Governors, Breast Cancer Committee, and Breast Translational Medicine Subcommittee.

Dr. Schott is a medical oncologist with a clinical emphasis on breast cancer. A Southerner at heart, Dr. Schott completed her undergraduate training at the University of South Alabama in Mobile in 1986. She remained at South Alabama for her medical school training, then completed a residency in internal medicine at the University of Virginia in Charlottesville.

After a year in private practice, Dr. Schott came to the University of Michigan through the medical oncology fellowship program in 1993. She joined the faculty in 1996. Her primary research interest is in therapeutic and translational clinical trials, especially as they apply to breast cancer.